Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tocilizumab - Chugai Pharmaceutical/Roche

Drug Profile

Tocilizumab - Chugai Pharmaceutical/Roche

Alternative Names: Actemra; ACTPen; Anti-IL-6 receptor antibody - Chugai; Anti-interleukin-6 receptor antibody - Chugai; Atlizumab; HPM-1; MRA; MRA - Chugai; MRA-SC; R-1569; RG-1569; rhPM-1; RO4877533; RoActemra

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Chugai Pharmaceutical; Osaka University
  • Developer Assistance Publique Hopitaux de Paris; Biomedical Advanced Research and Development Authority; Charite - Universitatsmedizin Berlin; Chugai Pharmaceutical; Hospital for Special Surgery; JW Pharmaceutical; Roche; University Hospital Inselspital; University Hospital Tubingen; University of Bern; University of Pittsburgh
  • Class Anti-inflammatories; Antineoplastics; Antirheumatics; Immunotherapies; Monoclonal antibodies; Skin disorder therapies; Vascular disorder therapies
  • Mechanism of Action Interleukin 6 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Drug hypersensitivity; Giant lymph node hyperplasia; Vasculitis; Systemic scleroderma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed COVID 2019 infections; COVID-19 pneumonia; Drug hypersensitivity; Giant cell arteritis; Giant lymph node hyperplasia; Juvenile rheumatoid arthritis; Rheumatoid arthritis; Systemic scleroderma
  • Registered Adult-onset Still's disease; Vasculitis
  • Phase III Osteoarthritis
  • Phase II Amyotrophic lateral sclerosis; Dermatomyositis; Familial Mediterranean fever; Polymyalgia rheumatica; Polymyositis; Pulmonary arterial hypertension; Schnitzler syndrome
  • Phase I/II Urogenital cancer
  • Phase I Pancreatic cancer
  • No development reported Chronic lymphocytic leukaemia
  • Discontinued Ankylosing spondylitis; Crohn's disease; Multiple myeloma; Systemic lupus erythematosus

Most Recent Events

  • 13 Sep 2023 Regulatory submission withdrawn for Systemic scleroderma in European Union (SC)
  • 09 May 2023 Registered for COVID-19 pneumonia in Taiwan (IV) before May 2023 (Chugai Pharmaceuticals pipeline, May 2023)
  • 23 Feb 2023 Tocilizumab is still in phase III trials for Systemic scleroderma in Belgium, Bulgaria, France, Germany, Greece, Denmark, Croatia, Netherlands, Lithuania, Hungary, Italy, Ireland, Romania, Switzerland, Spain, Portugal, Poland
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top